137 related articles for article (PubMed ID: 21042320)
81. Tet2 is a tumor suppressor in the preleukemic phase of T-cell acute lymphoblastic leukemia.
De Coninck S; Roels J; Lintermans B; T'Sas S; Taghon T; Curtis DJ; Pieters T; Goossens S; Van Vlierberghe P
Blood Adv; 2024 Jun; 8(11):2646-2649. PubMed ID: 38536906
[No Abstract] [Full Text] [Related]
82. A new path to leukemia with WIT.
Sardina JL; Graf T
Mol Cell; 2015 Feb; 57(4):573-574. PubMed ID: 25699704
[TBL] [Abstract][Full Text] [Related]
83. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia.
Tiacci E; Grossmann V; Martelli MP; Kohlmann A; Haferlach T; Falini B
Haematologica; 2012 Jan; 97(1):3-5. PubMed ID: 22210327
[No Abstract] [Full Text] [Related]
84. Dangerous Liaisons between Tet2 Mutation, Inflammatory Monocytes, and Leukemogenesis.
Pietras EM; DeGregori J
Cancer Discov; 2022 Oct; 12(10):2234-2236. PubMed ID: 36196576
[TBL] [Abstract][Full Text] [Related]
85. The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor.
Pettirossi V; Venanzi A; Spanhol-Rosseto A; Schiavoni G; Santi A; Tasselli L; Naccari M; Pensato V; Pucciarini A; Martelli MP; Drexler H; Falini B; Tiacci E
Leukemia; 2023 Feb; 37(2):473-477. PubMed ID: 36635390
[No Abstract] [Full Text] [Related]
86. TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study.
Mallo M; Osca G; Solórzano J; Arenillas L; Florensa L; Solé F
Haematologica; 2010 Oct; 95(10):1798-800. PubMed ID: 20595094
[No Abstract] [Full Text] [Related]
87. Human TET2 bridges cancer and immunity.
Zhang Q; Casanova JL
Blood; 2020 Aug; 136(9):1018-1019. PubMed ID: 32853377
[No Abstract] [Full Text] [Related]
88. Inhibitors of fatty acid oxidation enhance death of acute myeloid leukemia cells lacking NIX or SQSTM1.
Tcheng M; Samudio I; Spagnuolo PA
Leuk Lymphoma; 2020 Mar; 61(3):741-744. PubMed ID: 31707904
[No Abstract] [Full Text] [Related]
89. Cancer: Beyond the C.
Harjes U
Nat Rev Drug Discov; 2017 Sep; 16(10):678-679. PubMed ID: 28959947
[No Abstract] [Full Text] [Related]
90. Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients.
Chatzikalil E; Roka K; Diamantopoulos PT; Rigatou E; Avgerinou G; Kattamis A; Solomou EE
J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610812
[TBL] [Abstract][Full Text] [Related]
91. Acute myeloid leukemia: novel mutations and their clinical implications.
Makkar H; Majhi RK; Goel H; Gupta AK; Chopra A; Tanwar P; Seth R
Am J Blood Res; 2023; 13(1):12-27. PubMed ID: 36937458
[TBL] [Abstract][Full Text] [Related]
92. Mammalian DNA methylome dynamics: mechanisms, functions and new frontiers.
Wei A; Wu H
Development; 2022 Dec; 149(24):. PubMed ID: 36519514
[TBL] [Abstract][Full Text] [Related]
93. Correlation of TET-2 Levels with Disease Evaluation in AMI Patients.
Wang Q; Fu S; Li S; Huang X; Wang H
Contrast Media Mol Imaging; 2022; 2022():9983071. PubMed ID: 35965615
[TBL] [Abstract][Full Text] [Related]
94. Changes in DNA 5-Hydroxymethylcytosine Levels and the Underlying Mechanism in Non-functioning Pituitary Adenomas.
Xu Y; Niu Y; Deng K; Pan H; Feng F; Gong F; Tong WM; Chen S; Lu L; Wang R; You H; Yao Y; Zhu H
Front Endocrinol (Lausanne); 2020; 11():361. PubMed ID: 32774324
[TBL] [Abstract][Full Text] [Related]
95. Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome.
Oh YJ; Shin DY; Hwang SM; Kim SM; Im K; Park HS; Kim JA; Song YW; Márquez A; Martín J; Lee DS; Park JK
Korean J Intern Med; 2020 Mar; 35(2):457-464. PubMed ID: 31640337
[TBL] [Abstract][Full Text] [Related]
96. Epigenetic dysregulation of
García MG; Carella A; Urdinguio RG; Bayón GF; Lopez V; Tejedor JR; Sierra MI; García-Toraño E; Santamarina P; Perez RF; Mangas C; Astudillo A; Corte-Torres MD; Sáenz-de-Santa-María I; Chiara MD; Fernández AF; Fraga MF
Oncotarget; 2018 May; 9(40):25922-25934. PubMed ID: 29899831
[TBL] [Abstract][Full Text] [Related]
97. Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features.
Manso R; González-Rincón J; Rodríguez-Justo M; Roncador G; Gómez S; Sánchez-Beato M; Piris MA; Rodríguez-Pinilla SM
Oncotarget; 2018 Mar; 9(22):16124-16133. PubMed ID: 29662631
[TBL] [Abstract][Full Text] [Related]
98. Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.
Aziz H; Ping CY; Alias H; Ab Mutalib NS; Jamal R
Front Pharmacol; 2017; 8():897. PubMed ID: 29270125
[TBL] [Abstract][Full Text] [Related]
99. Molecular landscape in acute myeloid leukemia: where do we stand in 2016.
Al-Issa K; Nazha A
Cancer Biol Med; 2016 Dec; 13(4):474-482. PubMed ID: 28154779
[TBL] [Abstract][Full Text] [Related]
100. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
